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Diabetes
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OBJECTIVE— To estimate and compare associations of alanine aminotransferase (ALT) and
-glutamyltransferase (GGT) with incident diabetes.
RESEARCHDESIGNANDMETHODS— ALT and GGT were studied as determinants
of diabetes in the British Women’s Heart and Health Study, a cohort of 4,286 women 60–79
years old (median follow-up 7.3 years). A systematic review and a meta-analysis of 21 prospec-
tive, population-based studies of ultrasonography, which diagnosed nonalcoholic fatty liver
disease (NAFLD), ALT, and GGT as determinants of diabetes, were conducted, and associations
of ALT and GGT with diabetes were compared.
RESULTS— Ultrasonography-diagnosed NAFLD was associated with more than a doubling
in the risk of incident diabetes (three studies). ALT and GGT both predicted diabetes. The fully
adjusted hazard ratio (HR) for diabetes per increase in one unit of logged ALT was 1.83 (95% CI
1.57–2.14, I2  8%) and for GGT was 1.92 (1.66–2.21, I2  55%). To directly compare ALT
and GGT as determinants of diabetes, the fully adjusted risk of diabetes in the top versus bottom
fourth of the ALT and GGT distributions was estimated using data from studies that included
results for both markers. For ALT, the HR was 2.02 (1.59–2.58, I2 27%), and for GGT the HR
was 2.94 (1.98–3.88, I2  20%), suggesting that GGT may be a better predictor (P  0.05).
CONCLUSIONS— Findings are consistent with the role of liver fat in diabetes pathogenesis.
GGT may be a better diabetes predictor than ALT, but additional studies with directly deter-
mined liver fat content, ALT, and GGT are needed to confirm this finding.
Diabetes Care 32:741–750, 2009
N onalcoholic fatty liver disease(NAFLD) is characterized by accu-mulation of fat in the liver, with or
without inflammation, fibrosis, and cir-
rhosis, in the absence of substantial alco-
hol consumption or other causes of liver
disease such as viral hepatitis. In large ep-
idemiological studies, NAFLD and liver
fat content (a continuum) are commonly
revealed by elevations in alanine amino-
transferase (ALT), -glutamyltransferase
(GGT), and ultrasonography.
High rates of elevated GGT levels
were noted among diabetic patients over
40 years ago (1). Cross-sectional associa-
tions between abnormal GGT and dysgly-
cemic states were also documented in the
1980s (e.g., the study by Ford et al. [2]).
However, cross-sectional studies cannot
determine causality because in most cases
it is impossible to ascertain the temporal
sequence between the events studied. The
first longitudinal study to examine the as-
sociation of a biomarker of NAFLD with
incident diabetes was published in 1998
(3). Since then, both ALT and GGT, even
within the normal range, have been re-
ported to predict incident diabetes.
However, while some studies have dem-
onstrated a stronger association be-
tween GGT and diabetes than between
ALT and diabetes (4,5), other studies
have reported the opposite (6).
To our knowledge, no previous pub-
lication has systematically reviewed and
meta-analyzed all prospective studies of
the association between NAFLD and its
markers with future diabetes risk. We are
also unaware of any studies that have
compared the magnitude of the relative
associations between ALT and GGT with
diabetes risk, despite claims for one or the
other being a better marker of liver fat and
thus diabetes risk. We therefore exam-
ined the separate associations of ALT and
GGT with incident diabetes in a popula-
tion of older British women and under-
took a systematic review and meta-
analysis of prospective population-based
studies assessing the associations of
NAFLD, ALT, or GGT with diabetes. Of
note, while aspartate aminotransferase
has also been assessed in some studies
(e.g., in the study by Andre´ et al. [4]), it is
not as sensitive or specific to liver damage
as ALT or GGT (7) and is therefore not
addressed here.
RESEARCH DESIGN AND
METHODS
British Women’s Heart and Health
Study
Full details of the selection of participants
and measurements have been previously
reported (8–10). A total of 4,286 women,
aged 60 –79 years, were randomly re-
cruited from 23 British towns. Baseline
data (self-completed questionnaire, re-
search nurse interview, physical examina-
tion, and medical record review) were
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collected between 1999 and 2001. These
women have been followed up for a me-
dian of 7.3 years, to September 2007, by a
detailed review of their medical records
conducted every 2 years and by a self-
completed questionnaire. Informed con-
sent was obtained from the women, and
the approval of both the local and multi-
center ethics committees was obtained for
the study.
Levels of GGT and ALT were deter-
mined in fresh serum samples using an
automated analyzer (Technicon Sequen-
tial Multiple Analyzer; Technicon Instru-
ments Corporation, Tarrytown, NY).
Waist and hip circumference, lipids, fast-
ing glucose and insulin, and blood pres-
sure were measured using standard
methods as previously described. Infor-
mation on smoking, physical activity, so-
cial class, and alcohol consumption was
obtained from a self-completed question-
naire and nurse interview (9).
Insulin resistance was estimated ac-
cording to the homeostasis model assess-
ment (HOMA) as the product of fasting
glucose (millimoles per liter) and insulin
(microunits per milliliter) divided by the
constant 22.5 (11). Baseline diabetes (for
exclusion of these cases) was defined ac-
cording to the World Health Organiza-
tion criteria as any woman with a doctor’s
diagnosis of diabetes (based on medical
records review and self-report) and/or
with a fasting glucose concentration 7
mmol/l (12). Incident cases of diabetes
were defined as either a self-report of a
doctor diagnosis of diabetes or evidence
of diabetes in the follow-up medical
record reviews.
Cox proportional hazards regression
models were used to examine associations
of exposures with incident diabetes in
those with no evidence of diabetes at
baseline. In the Cox proportional hazards
regression models, the participant’s age
was the time axis and risk was assessed
from the date of baseline examination for
each woman. ALT and GGT were ex-
pressed in units of SD of their respective
distributions. Contributions to risk were
censored at the date of diagnosis or death
from any other cause or at the end of the
follow-up period (30 September 2007)
for those who remained alive and free of
diabetes.
Systematic review and meta-analysis
PubMed and EMBASE (Excerpta Medica
Database) were systematically searched
by A.F. in February 2008 for all prospec-
tive population-based studies evaluating
the association among NAFLD (diag-
nosed by any imaging technique), ALT,
GGT, and incident diabetes. No language
restrictions were applied. Abstracts were
scanned, relevant full-text publications
were obtained, and inclusion criteria were
applied (i.e., prospective studies con-
ducted in general populations). Two in-
dependent reviewers (A.F. and D.A.L.)
abstracted data. Reference lists of ob-
tained articles were hand searched for ad-
ditional potential studies. Study authors
were contacted for additional data or clar-
ification when required.
Two sets of meta-analyses were un-
dertaken to reflect the two aims of this
study. In the first set, a separate meta-
analysis was conducted for each NAFLD
marker, maximizing data use regardless
of whether they provided data on ultra-
sound-defined NAFLD, ALT only, GGT
only, or any combination of these. In
these analyses, the assumption was that
all study results for ALT (GGT or ultra-
sound) were part of the same distribution
but not that the true effect was the same in
all studies; therefore, a random-effects
model was used, though we did also
check our assumption for this random ef-
fect using the I2 measure, which quanti-
fies the percentage of total variation across
studies that is due to heterogeneity rather
than chance (13).
Because different studies presented
results on different scales (e.g., risk ratios
[RRs] for quantiles of ALT or GGT com-
pared with the lowest quantile or per cat-
egory or logged unit per liter), for the first
meta-analysis (of all studies) a standard
statistical method was used to estimate
the log hazard ratio (HR) per log unit in-
crease in ALT or GGT, together with its SE
(14,15). Results are presented as the HR
per unit change in ALT or GGT on a log
scale.
When data were presented according
to quantiles or categories of ALT or GGT,
the median or mean in each group, when
reported, was used. When these were not
reported, the mean in each group was es-
timated based on the distribution of sub-
jects across groups, as outlined by Cheˆne
and Thompson (15). All exposure (GGT
and ALT) levels were converted to the log-
normal scale if not already presented as
such. The log HR per 1 unit/l increase was
then estimated using the method of
Greenland and Longnecker (14). This al-
lows for correlations between HRs that are
related to the same reference group.
The objective of the second meta-
analysis was to directly compare the asso-
ciations of ALT and GGT with diabetes.
We decided a priori to limit this second
analysis to results of studies that provided
estimates for both ALT and GGT in the
same population in order to ensure the
comparability of the estimates for ALT
and GGT. Furthermore, only studies for
which we could obtain results in which
ALT and GGT had been standardized (to
account for their different distributions)
were included. The most common
method used to standardize ALT and
GGT was to present results per fourths of
the ALT and GGT distributions. There-
fore, we combined the RRs in the top ver-
sus the bottom fourth of the ALT and
GGT. A fixed-effects model was used,
thus assuming that the true effect in all
studies was the same and any difference
between study results was due to chance
alone, and this assumption was checked
using the I2 measure (13).
When possible, data were extracted
separately for men and women. The effect
of duration of follow-up on study results
was assessed by meta-regression. Small-
study effects such as publication bias were
examined by using a funnel plot (16) and
formally tested using the Egger test (17).
RESULTS
British Women’s Heart and Health
Study
Data on diabetes at baseline were available
for 3,829 women (89% of 4,286), of whom
377 had diabetes and were excluded from
the analysis. Of the remaining 3,452
women, 3,041 (88% of 3,452) had com-
plete data on all covariables (Table 1). Char-
acteristics of included women by diabetes
status at the end of follow-up are presented
Table 1—HRs (95% CI) of incident diabetes per SD change of natural logged ALT and GGT
Model 1 Model 2 Model 3 Model 4
ALT 1.50 (1.27–1.74) 1.51 (1.29–1.77) 1.37 (1.15–1.64) 1.20 (0.99–1.44)
GGT 1.55 (1.34–1.79) 1.55 (1.35–1.79) 1.46 (1.25–1.71) 1.24 (1.04–1.48)
Model 1, adjusted for age; model 2, model 1 adjustment plus alcohol consumption; model 3, model 2
adjustments plus childhood and adult social class, physical activity, and smoking; model 4, model 3
adjustments plus HOMA, waist-to-hip ratio, triglycerides, HDL cholesterol, and systolic blood pressure.
ALT, GGT, and diabetes
742 DIABETES CARE, VOLUME 32, NUMBER 4, APRIL 2009
in Table A1 (available in an online appendix
at http://care.diabetesjournals.org/cgi/
content/full/dc08-1870/DC1). Women
with diabetes at the end of follow-up were
older; had higher age-adjusted mean BMI,
waist-to-hip ratio, ALT, GGT, triglycerides,
glucose, and HOMA; and had lower HDL
cholesterol. More of the women with inci-
dent diabetes exercised for2 h per week,
and more also had a history of smoking.
During 281,081 person-years of fol-
low-up, 112 women were diagnosed with
diabetes, yielding a rate of 5.3 per 1,000
person-years (95% CI 4.4 – 6.4). Both
ALT and GGT were associated with inci-
dent diabetes, even when adjustment was
made for alcohol consumption (Table 1)
and other potential confounders. When
components of the metabolic syndrome
were added to the model, the associations
of both ALT and GGT with incident dia-
betes were attenuated toward the null.
The 95% CI crossed the null for ALT but
not for GGT. However, the magnitude of
associations of ALT with diabetes and of
GGT with diabetes was comparable in all
four models, as was the degree of attenu-
ation of age-adjusted estimates.
Systematic review and meta-analysis
The electronic search (crossing terms for
ALT, GGT, liver steatosis, and diabetes)
yielded 236 potentially relevant publica-
tions, of which 20 studied prospective
population-based cohorts and assessed
baseline ultrasonography-diagnosed
NAFLD, ALT, and/or GGT and their asso-
ciations with incident diabetes.
Ultrasound-diagnosed NAFLD
Three studies (18–20) (summarized in
Table 2) assessed ultrasound-diagnosed
NAFLD as a determinant of incident dia-
betes. No studies that used any other di-
agnostic test to ascertain NAFLD in its
association with incident diabetes were
retrieved. All three studies were con-
ducted in Asian populations, and in all
three there was evidence that ultrasound-
diagnosed NAFLD was associated with
diabetes risk. When estimates from these
studies were meta-analyzed (using the es-
timate of mild vs. no NAFLD from the
study by Kim et al. [18]), the pooled RR
was 2.52 (95% CI 1.07–5.96), but there
was evidence of considerable heterogene-
ity between studies (I2  90%).
ALT and GGT
Study characteristics of the 18 prospec-
tive population-based studies of the asso-
ciations of ALT and/or GGT with incident
diabetes are also summarized in Table 2.
Ten studies (4–6,21–28) (including the
current analysis of the British Women’s
Heart and Health Study [BWHHS]) as-
sessed both ALT and GGT as predictors of
diabetes, an additional three studies
looked at ALT only (29–31), and another
four studies looked at the association of
GGT with diabetes risk (3,32–34). Age-
adjusted and fully adjusted study results
examining (natural logged) ALT and GGT
as determinants of incident diabetes were
pooled (separately).
A change in one logged unit in ALT
was associated with an HR of 3.05 (95%
CI 2.59–3.59, I2  26%, 13 compari-
sons) and in GGT 2.56 (2.31–2.84, I2 
32%, 17 comparisons) (online appendix
Fig. A1). The meta-analysis of fully ad-
justed results for both ALT and GGT are
presented in Fig. 1. The fully adjusted HR
for diabetes per increase in one unit of
logged ALT was 1.85 (1.57–2.18, I2 19,
14 comparisons), and in one unit of
logged GGT the HR was 1.92 (1.66–2.21,
I2  55%, 18 comparisons).
No strong evidence was found for the
presence of a small-studies effect for ALT
or GGT. There was also no strong evi-
dence of an association between duration
of follow-up and study results (all P
0.69).
Comparing associations of ALT and
GGT with incident diabetes
Seven studies (including the BWHHS)
contributed to the analysis of ALT and
GGT categorized in fourths as predictors
of diabetes (4,5,21,22,24,25). Additional
studies assessed both ALT and GGT; how-
ever, one used fifths (26,27), another
used tenths (6), and a final study (28)
used fourths but did not present results in
full and therefore could not be included
in this analysis. Age-adjusted pooled anal-
yses of the included studies are presented
in online appendix Figure A2. The RR in
the top versus the bottom quartile of ALT
was 4.42 (95% CI 3.61–5.42, I2 42%),
and for GGT it was 5.87 (4.63–7.44, I2
21%). The fully adjusted RR for ALT was
2.02 (1.59–2.58, I2 27%) and for GGT
2.94 (1.98–3.88, I2  20%) (Fig. 2). Ac-
cording to a formal statistical test for het-
erogeneity between estimates for ALT and
GGT, there was some evidence suggesting
that pooled estimates for GGT were larger
than those for ALT (age-adjusted results,
P  0.08, and fully adjusted results, P 
0.05).
However, repeating the analysis after
excluding results for women in the DESIR
(Data From the Epidemiological Study on
the Insulin Resistance Syndrome) cohort
(4), which was the only study that showed
a potential protective effect of ALT, re-
sulted in greater pooled estimates for
GGT (HR 2.91 [95% CI 2.19–3.85]) than
for ALT (2.12 [1.66–2.72]) but no strong
evidence for heterogeneity between the
estimates (P0.10 for both age-adjusted
and fully adjusted results).
CONCLUSIONS— Ultrasound-di-
agnosed NAFLD, ALT, and GGT all pre-
dicted diabetes risk. NAFLD defined by
ultrasound was associated with more than
a doubling of the risk of incident diabetes.
In a meta-analysis of fully adjusted results
(albeit variably adjusted) of all popula-
tion-based, systematically identified pro-
spective studies, a 1 unit/l increase of
natural logged ALT was associated with
an 85% increase in diabetes risk and a 1
unit/l increase of natural logged GGT was
associated with a 92% increase in diabetes
risk.
A second meta-analysis that assessed
the association of both ALT and GGT (us-
ing fourths of their distribution) with in-
cident diabetes in the same populations
was performed. Belonging to the top
fourth of the GGT distribution was asso-
ciated with a 194% increase in the risk of
diabetes compared with risk increase as-
sociated with belonging to the bottom
fourth. For ALT, the corresponding in-
crease in the risk of diabetes was 102%,
with formal evidence of heterogeneity be-
tween these two estimates (both based on
fully adjusted models).
There are two possible explanations
for the potentially stronger association of
GGT with diabetes compared with that of
ALT. First, both ALT and GGT are bi-
omarkers of liver fat, but GGT may simply
be the better marker. In light of the pau-
city of relevant evidence as to which liver
enzyme better reflects liver fat content,
this explanation cannot be ruled out.
However, GGT is present on the surface of
most cell types and is highly active in or-
gans other than the liver, such as the kid-
ney and pancreas (35). Therefore, ALT is
considered a more liver-specific marker
than GGT. GGT is the enzyme responsi-
ble for the extracellular catabolism of an-
tioxidant glutathione (36) and may be
linked to greater oxidative stress (37). Be-
cause oxidative stress has been implicated
in insulin resistance, diabetes, and cardio-
vascular disease (37,38), GGT’s poten-
tially stronger association with diabetes
may reflect its associations with several
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different processes relevant to diabetes
pathogenesis. This speculative suggestion
requires more data.
Although a stronger association of
GGT (compared with that of ALT) with
diabetes is biologically plausible, our re-
sults should be interpreted with caution.
The exclusion of a single observation sub-
stantially reduced the strength of evi-
dence that the associations of ALT and
GGT with incident diabetes were differ-
ent. In addition, some limitations should
be noted. Only 6 of the 10 studies that
presented results for both ALT and GGT
could be included in the meta-analyses of
the risk estimates in the top fourth of the
ALT and GGT distributions versus the
bottom fourth (despite our best efforts to
contact and obtain relevant information
from authors, results in the form neces-
sary to include the additional three stud-
ies were not forthcoming). An additional
limitation is that two of the studies in-
cluded in the systematic review could not
be included in the meta-analysis of all
studies as a result of missing information.
Attempts were made to obtain additional
results from study authors, but this was
not always possible. Limitations of the
BWHHS include the lack of oral glucose
tolerance testing at baseline, the use of
self-reported medical diagnoses of diabe-
tes at follow-up, a less robust measure of
insulin resistance (HOMA), and the inclu-
sion of women only. The latter is also the
study’s strength because 6 of the 18 stud-
ies do not include any women.
In conclusion, NAFLD and associated
elevations in liver enzymes are associated
with incident diabetes above and beyond
commonly measured diabetes risk fac-
tors. Results suggest that the association
of GGT with diabetes risk may be of
greater magnitude than that of ALT with
diabetes, but further studies are needed to
confirm this. In the meantime, raised lev-
els of both enzymes in the context of other
clinical features of insulin resistance (obe-
Figure 1— Meta-analysis of fully adjusted results of ALT and GGT as a determinant of incident diabetes.
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sity, hypertriglyceridemia, raised fasting
glucose, etc.) give good insight into excess
hepatic fat and thus elevated diabetes risk.
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